3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
113
Neoplasms
8
HER2-positive Breast Cancer
8
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Inflammatory Breast Neoplasms
4
Hematologic Neoplasms
3
Brain Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Locally Advanced Breast Cancer
2
HER2-positive Metastatic Breast Cancer
2
HER2-positive Early Breast Cancer
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Ductal, Breast
2
Breast Neoplasms, Male
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Interventions
Echocardiography
4
sacubitril and valsartan sodium hydrate drug combination
3
Standard of Care
3
Nutrition Assessment
3
Exercise
3
Electrocardiography
3
Carvedilol
3
dapagliflozin
2
Surveys and Questionnaires
2
Spironolactone
2
Ivabradine
2
Blood Specimen Collection
2
Atorvastatin
2
ziprasidone
1
pertuzumab
1
pegfilgrastim
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
Zolpidem
1
Watchful Waiting
1
Warfarin
1
Vincristine
1
Vecuronium Bromide
1
Vascular Stiffness
1
Vancomycin
1
Valsartan
1
Trastuzumab
1
Tranexamic Acid
1
Tobramycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Heart Failure
×
pertuzumab
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled